	US 12,226,456 B2
	Nasal powder formulation for treatment of hypoglycemia
Sankaram Mantripragada, Windsor, CO (US); Claude A. Piche, Verdun (CA); and Jo Jan Filip Van Betsbrugge, Laval (CA)
Assigned to Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, CA (US)
Filed by Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, CA (US)
Filed on Feb. 4, 2019, as Appl. No. 16/266,640.
Application 16/266,640 is a continuation of application No. 15/545,332, granted, now 10,213,487, previously published as PCT/US2016/018003, filed on Feb. 16, 2016.
Claims priority of provisional application 62/117,031, filed on Feb. 17, 2015.
Prior Publication US 2019/0282666 A1, Sep. 19, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/26 (2006.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 31/724 (2006.01); A61K 47/12 (2006.01); A61K 47/24 (2006.01); A61M 15/00 (2006.01); A61M 15/08 (2006.01)

CPC A61K 38/26 (2013.01) [A61K 9/0043 (2013.01); A61K 9/145 (2013.01); A61K 9/146 (2013.01); A61K 31/724 (2013.01); A61K 47/12 (2013.01); A61K 47/24 (2013.01); A61M 15/0065 (2013.01); A61M 15/08 (2013.01); A61M 2202/064 (2013.01)]

6 Claims

1. A powder composition comprising glucagon (SEQ ID NO:1), a phospholipid surfactant selected from dilauroylphosphatidylglycerol and dodecylphosphocholine, and α-cyclodextrin, wherein the glucagon, the phospholipid surfactant and α-cyclodextrin are present in formulation selected from the group consisting of:

a. 5 wt % glucagon, 25 wt % phospholipid surfactant, wherein the phospholipid surfactant is dilauroylphosphatidylglycerol, and 70 wt % α-cyclodextrin; and

b. 5 wt % glucagon, 25 wt % phospholipid surfactant, wherein the phospholipid surfactant is dodecylphosphocholine, and 70 wt % α-cyclodextrin.